Investigating FGFR-targeted therapy
Discover more about urinary tract and bladder cancer
Learn about PROPEL and PROPEL 2
12.01.2020
BridgeBio Pharma and Affiliate QED Therapeutics Announce FDA Acceptance of New Drug Application for Infigratinib for the Treatment of Cholangiocarcinoma
08.11.2020
BridgeBio Pharma Expands Reach Into China and Other Major Asian Markets Through Strategic Collaboration With Perceptive Advisors-Founded Company, LianBio
07.28.2020
Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma
I am an HCP and would like to someone from QED to contact me.
*Required fields.
Communication Agreement
By completing this form and clicking the SUBMIT button, you understand and hereby consent to your personal information being stored on a database in the United States and accessible to QED Therapeutics for purposes such as marketing programs from QED Therapeutics, disseminating information about research from QED Therapeutics regarding infigratinib and related health conditions, and obtaining feedback about our products and services. You may request access to, removal, or correction of your personal information by sending an email to: medinfo@QEDTx.com. Please review the full QED Therapeutics privacy policy for more information on your rights with respect to your personal information. If you are a resident of the European Union, please note that by submitting your information to QED through this form, you are expressly consenting to transfer of your personal data to the United States.
75 Federal Street San Francisco, CA 94107
1-877-280-5655
Leaving Site
By selecting “Proceed” you will leave QEDTx.com and be directed to an external website.
Cancel Proceed